Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.43
CRDC's Cash to Debt is ranked higher than
61% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. CRDC: 5.43 )
Ranked among companies with meaningful Cash to Debt only.
CRDC' s Cash to Debt Range Over the Past 10 Years
Min: 0.36  Med: 6.23 Max: No Debt
Current: 5.43
Equity to Asset 0.56
CRDC's Equity to Asset is ranked lower than
58% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. CRDC: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
CRDC' s Equity to Asset Range Over the Past 10 Years
Min: -5.64  Med: 0.68 Max: 0.86
Current: 0.56
-5.64
0.86
F-Score: 3
Z-Score: -13.93
M-Score: -6.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -375.98
CRDC's Operating margin (%) is ranked lower than
93% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.98 vs. CRDC: -375.98 )
Ranked among companies with meaningful Operating margin (%) only.
CRDC' s Operating margin (%) Range Over the Past 10 Years
Min: -628.19  Med: -399.38 Max: -26.6
Current: -375.98
-628.19
-26.6
Net-margin (%) -386.12
CRDC's Net-margin (%) is ranked lower than
93% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.15 vs. CRDC: -386.12 )
Ranked among companies with meaningful Net-margin (%) only.
CRDC' s Net-margin (%) Range Over the Past 10 Years
Min: -641.54  Med: -376.83 Max: -26.56
Current: -386.12
-641.54
-26.56
ROE (%) -86.57
CRDC's ROE (%) is ranked lower than
91% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.01 vs. CRDC: -86.57 )
Ranked among companies with meaningful ROE (%) only.
CRDC' s ROE (%) Range Over the Past 10 Years
Min: -171.5  Med: -83.84 Max: -45.86
Current: -86.57
-171.5
-45.86
ROA (%) -60.06
CRDC's ROA (%) is ranked lower than
89% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. CRDC: -60.06 )
Ranked among companies with meaningful ROA (%) only.
CRDC' s ROA (%) Range Over the Past 10 Years
Min: -108.53  Med: -58.99 Max: -33.08
Current: -60.06
-108.53
-33.08
ROC (Joel Greenblatt) (%) -910.04
CRDC's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.53 vs. CRDC: -910.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRDC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1119.89  Med: -764.41 Max: -341.72
Current: -910.04
-1119.89
-341.72
Revenue Growth (3Y)(%) -34.70
CRDC's Revenue Growth (3Y)(%) is ranked lower than
95% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. CRDC: -34.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRDC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -29.70 Max: 13.6
Current: -34.7
0
13.6
EBITDA Growth (3Y)(%) -21.60
CRDC's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. CRDC: -21.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRDC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55  Med: -26.60 Max: 33.2
Current: -21.6
-55
33.2
EPS Growth (3Y)(%) -21.40
CRDC's EPS Growth (3Y)(%) is ranked lower than
78% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. CRDC: -21.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRDC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.8  Med: -25.90 Max: 33
Current: -21.4
-51.8
33
» CRDC's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CRDC Guru Trades in Q2 2015

PRIMECAP Management 6,013,500 sh (unchged)
» More
Q3 2015

CRDC Guru Trades in Q3 2015

PRIMECAP Management 6,013,500 sh (unchged)
» More
Q4 2015

CRDC Guru Trades in Q4 2015

Jim Simons 136,622 sh (New)
PRIMECAP Management 6,013,500 sh (unchged)
» More
Q1 2016

CRDC Guru Trades in Q1 2016

Jim Simons 49,872 sh (+265.04%)
PRIMECAP Management 601,350 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRDC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:XKRX:131030, XPAR:ALMED, NAS:CASM, ASX:CLV, ASX:CMP, AMEX:ISR » details
Traded in other countries:C5V1.Germany,
Cardica Inc is engaged in commercializing and developing its MicroCutter XCHANGE 30 based on its proprietary staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Cardica Inc was incorporated in the state of Delaware on October 15, 1997, as Vascular Innovations, Inc. On November 26, 2001, the Company changed its name to Cardica, Inc. The Company is commercializing and developing the MicroCutter XCHANGE 30 based on its proprietary staple-on-a-strip technology intended for use by thoracic, pediatric, bariatric, colorectal and general surgeons. The MicroCutter XCHANGE 30, which is currently commercially-available, is a cartridge based microcutter device with a 5 millimeter shaft diameter and a 30 millimeter staple line currently approved for use in the United States for specified indications of use, and in the European Union, or EU, for a broader range of specified indications of use.

Top Ranked Articles about Cardica Inc

Weekly CFO Buys Highlight: Brooks Automation, Cardica, Twitter Recent insider buys from company CFOs
According to GuruFocus Insider Data, the recent CFO buys were: Brooks Automation Inc. (NASDAQ:BRKS), Cardica Inc. (NASDAQ:CRDC) and Twitter Inc. (NYSE:TWTR). Read more...

Ratios

vs
industry
vs
history
P/S 5.80
CRDC's P/S is ranked lower than
79% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. CRDC: 5.80 )
Ranked among companies with meaningful P/S only.
CRDC' s P/S Range Over the Past 10 Years
Min: 1.52  Med: 12.22 Max: 34.87
Current: 5.8
1.52
34.87
Current Ratio 6.33
CRDC's Current Ratio is ranked higher than
87% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. CRDC: 6.33 )
Ranked among companies with meaningful Current Ratio only.
CRDC' s Current Ratio Range Over the Past 10 Years
Min: 1.7  Med: 6.05 Max: 21.42
Current: 6.33
1.7
21.42
Quick Ratio 5.93
CRDC's Quick Ratio is ranked higher than
91% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. CRDC: 5.93 )
Ranked among companies with meaningful Quick Ratio only.
CRDC' s Quick Ratio Range Over the Past 10 Years
Min: 1.26  Med: 5.71 Max: 20.95
Current: 5.93
1.26
20.95
Days Inventory 123.65
CRDC's Days Inventory is ranked higher than
52% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. CRDC: 123.65 )
Ranked among companies with meaningful Days Inventory only.
CRDC' s Days Inventory Range Over the Past 10 Years
Min: 71.03  Med: 104.10 Max: 149.78
Current: 123.65
71.03
149.78
Days Sales Outstanding 38.11
CRDC's Days Sales Outstanding is ranked higher than
85% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.03 vs. CRDC: 38.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRDC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.01  Med: 32.06 Max: 71.28
Current: 38.11
9.01
71.28
Days Payable 101.73
CRDC's Days Payable is ranked higher than
75% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.30 vs. CRDC: 101.73 )
Ranked among companies with meaningful Days Payable only.
CRDC' s Days Payable Range Over the Past 10 Years
Min: 37.65  Med: 72.36 Max: 109.22
Current: 101.73
37.65
109.22

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.00
CRDC's Price/Net Cash is ranked higher than
89% of the 53 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.73 vs. CRDC: 3.00 )
Ranked among companies with meaningful Price/Net Cash only.
CRDC' s Price/Net Cash Range Over the Past 10 Years
Min: 1.32  Med: 6.60 Max: 113.16
Current: 3
1.32
113.16
Price/Median PS Value 0.47
CRDC's Price/Median PS Value is ranked higher than
92% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.06 vs. CRDC: 0.47 )
Ranked among companies with meaningful Price/Median PS Value only.
CRDC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.04 Max: 2.14
Current: 0.47
0.19
2.14
Earnings Yield (Greenblatt) (%) -55.19
CRDC's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. CRDC: -55.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRDC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -181.07  Med: 0.00 Max: 0
Current: -55.19
-181.07
0

More Statistics

Revenue (TTM) (Mil) $4.04
EPS (TTM) $ -1.77
Beta-1.50
Short Percentage of Float0.90%
52-Week Range $1.09 - 5.20
Shares Outstanding (Mil)8.93

Analyst Estimate

Jun16 Jun17 Jun18 Jun19
Revenue (Mil $) 4 4 16 35
EPS ($) -1.74 -1.80 -1.23 -0.32
EPS without NRI ($) -1.74 -1.80 -1.23 -0.32
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CRDC

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: Brooks Automation, Cardica, Twitter Feb 21 2016 
Does the OSV Rating System Really Work? Feb 17 2016 
CARDICA, INC. Reports Operating Results (10-Q) Feb 11 2011 
CARDICA, INC. Reports Operating Results (10-Q) Nov 15 2010 
CARDICA, INC. Reports Operating Results (10-Q) May 17 2010 
Weekly CFO Buy Highlight: CARDICA, NewBridge Bancorp, WESCO International, PrivateBancorp Inc., Syno Nov 07 2009 
CARDICA, INC. Reports Operating Results (10-Q) Nov 06 2009 
CARDICA, INC. (CRDC) CFO Robert Y Iv Newell buys 16,000 Shares Nov 04 2009 
Weekly CFO Buy Highlights: Cardica, Inc. (CRDC), American International Industries Inc (AMIN) Oct 10 2009 
CARDICA, INC. (CRDC) CEO Bernard A Hausen buys 19,960 Shares Oct 02 2009 

More From Other Websites
CARDICA INC Financials May 19 2016
Cardica Announces Positive Results of Long-Term Evaluation of Company’s C-Port® System for Vein... May 17 2016
Cardica Announces Positive Results of Long-Term Evaluation of Company’s C-Port® System for Vein... May 17 2016
CARDICA INC Files SEC form 10-Q, Quarterly Report May 12 2016
Husam Balkhy, M.D. to Present Clinical Study Results of Cardica’s C-Port® Distal Anastomosis... May 11 2016
Husam Balkhy, M.D. to Present Clinical Study Results of Cardica’s C-Port® Distal Anastomosis... May 11 2016
Cardica, Inc. :CRDC-US: Earnings Analysis: Q3, 2016 By the Numbers May 11 2016
Cardica Inc Earnings Call scheduled for 4:30 pm ET today May 05 2016
Cardica Reports Fiscal 2016 Third Quarter Financial Results May 05 2016
CARDICA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 05 2016
Cardica Reports Fiscal 2016 Third Quarter Financial Results May 05 2016
5 Breakout Stocks Under $10 Set to Soar May 05 2016
Q3 2016 Cardica Inc Earnings Release - After Market Close May 05 2016
3 Medical Devices Stocks Set to Beat this Earnings Season May 04 2016
Is a Surprise Coming for Cardica (CRDC) This Earnings Season? May 04 2016
Cardica to Announce Fiscal 2016 Third Quarter Financial Results on Thursday, May 5, 2016 Apr 25 2016
Cardica to Announce Fiscal 2016 Third Quarter Financial Results on Thursday, May 5, 2016 Apr 25 2016
Cardica Announces First Procedures in U.S. Using MicroCutter XCHANGE® 30 Following Expanded FDA... Apr 18 2016
Cardica Announces First Procedures in U.S. Using MicroCutter XCHANGE® 30 Following Expanded FDA... Apr 18 2016
OxySure (OXYS) Ramps Up Production as Growth Continues Feb 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)